ClinicalTrials.gg

Program

Insulin Aspart

Also written as “insulin aspart”, “biphasic insulin aspart” and “Faster-acting insulin aspart”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Diabetes, Gestational, led by 9 companies.

Furthest: phase 4, since Nov 4, 2004139 company-led studies, 1 open or runningNext primary completion: Dec 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk1280 open or runningphase 4since Nov 4, 2004Jul 17, 2003none ahead
Amphastar Pharmaceuticals20 open or runningphase 3since Sep 12, 2022Sep 12, 2022none ahead
Geropharm20 open or runningphase 3since Sep 3, 2019Sep 3, 2019none ahead
Profil Institut für Stoffwechselforschung20 open or runningphase 1since Aug 8, 2007Aug 8, 2007none ahead
cequr-corporation10 open or runningno phasesince Mar 24, 2015Mar 24, 2015none ahead
defymed11 open or runningno phasesince Dec 3, 2021Dec 3, 2021Dec 2026NCT05221359
Sunshine Lake Pharma10 open or runningphase 3since Mar 6, 2023Mar 6, 2023none ahead
The United Laboratories International10 open or runningno phasesince May 6, 2026May 6, 2026none ahead
Tonghua Dongbao Pharmaceutical10 open or runningphase 3since Jun 5, 2015Jun 5, 2015none ahead

Also a collaborator on its studies: mylan-gmbh and Sanofi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 25, 2011.

  1. Jul 4, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02825251 · 472 enrolled · United States, Belgium, Canada and more
  2. Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
  3. Sep 15, 2016Phase 3 study in Diabetes MellitusNovo Nordisk · NCT02906917 · 532 enrolled · United States, Algeria, Czechia and more
  4. Oct 13, 2016Phase 1 study in Diabetes MellitusNovo Nordisk · NCT02933853 · 61 enrolled · Austria
  5. Jun 29, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03215498 · 58 enrolled · Germany
  6. Jan 5, 2018Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03407599 · 46 enrolled · Germany
  7. Jan 23, 2019Phase 2 study in Diabetes Mellitus, Type 1Novo Nordisk · NCT03816761 · 24 enrolled · United States
  8. Sep 3, 2019Geropharm's first study: phase 3 study in Diabetes MellitusNew to GeropharmGeropharm · NCT04079413 · 264 enrolled · Russian Federation
  9. Nov 29, 2019No phase study in Clamp StudyGeropharm · NCT04184466 · 26 enrolled · Russian Federation
  10. Dec 3, 2021defymed's first study: no phase study in Diabetes Mellitus, Type 1New to defymeddefymed · NCT05221359 · 8 planned · France
  11. Sep 12, 2022Amphastar Pharmaceuticals's first study: phase 3 study in PharmacokineticsNew to Amphastar PharmaceuticalsAmphastar Pharmaceuticals · NCT05539872 · 69 enrolled · United States
  12. Mar 6, 2023Sunshine Lake Pharma's first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
  13. Apr 24, 2026Phase 3 study in PharmacokineticsAmphastar Pharmaceuticals · NCT07560150 · 62 enrolled · United States
  14. May 6, 2026The United Laboratories International's first study: no phase study in Pharmacokinetics and PharmacodynamicsNew to The United Laboratories InternationalThe United Laboratories International · NCT07600944 · 44 enrolled · China

Ahead

  1. Dec 2026Primary completion: no phase study in Diabetes Mellitus, Type 1defymed · NCT05221359

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The newest 60 of 139 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07600944Pharmacokinetics and Pharmacodynamics · China–CompletedThe United Laboratories InternationalJun 13, 202644
NCT07560150Pharmacokinetics · United States3CompletedAmphastar PharmaceuticalsJun 22, 202662
NCT05802862Diabetes Mellitus · China3CompletedSunshine Lake PharmaAug 16, 2024414
NCT05539872Pharmacokinetics · United States3CompletedAmphastar PharmaceuticalsJan 29, 202369
NCT05221359Diabetes Mellitus, Type 1 · France–RecruitingdefymedDec 20268
NCT04184466Clamp Study · Russian Federation–CompletedGeropharmDec 19, 201826
NCT04079413Diabetes Mellitus · Russian Federation3CompletedGeropharmJan 21, 2020264
NCT03816761Diabetes Mellitus, Type 1 · United States2CompletedNovo NordiskMay 31, 201924
NCT03407599Diabetes Mellitus · Germany1CompletedNovo NordiskJul 5, 201846
NCT03215498Diabetes Mellitus · Germany1CompletedNovo NordiskNov 20, 201758
NCT02933853Diabetes Mellitus · Austria1CompletedNovo NordiskDec 21, 201761
NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more3CompletedNovo NordiskAug 31, 2017532
NCT02844790Healthy · China1CompletedNovo NordiskSep 26, 201624
NCT02825251Diabetes Mellitus · United States, Belgium, Canada and more3CompletedNovo NordiskJun 20, 2017472
NCT02762578Diabetes Mellitus · China3CompletedNovo NordiskMay 19, 2017543
NCT02670915Diabetes Mellitus · United States, Bulgaria, Czechia and more3CompletedNovo NordiskFeb 5, 2018834
NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more3CompletedNovo NordiskSep 4, 2016263
NCT02594033Diabetes Mellitus · Germany1CompletedNovo NordiskJan 28, 201646
NCT02568280Diabetes Mellitus · Austria1CompletedNovo NordiskApr 25, 201642
NCT02500706Diabetes Mellitus · United States, Austria, Bulgaria and more3CompletedNovo NordiskJul 17, 20171,108
NCT02491528Diabetes Mellitus · China3CompletedTonghua Dongbao PharmaceuticalAug 12, 2016563
NCT02419859Diabetes Mellitus, Type 2 · Austria–Completedcequr-corporationNov 201520
NCT02131246Diabetes Mellitus · Austria1CompletedNovo NordiskJul 201433
NCT02089451Diabetes Mellitus · Germany1CompletedNovo NordiskJun 6, 201421
NCT02035371Diabetes Mellitus · Germany1CompletedNovo NordiskJul 24, 201441
NCT02033239Diabetes Mellitus · Germany1CompletedNovo NordiskJun 201446
NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico3CompletedNovo NordiskJan 11, 2016501
NCT02003677Diabetes Mellitus · Germany1CompletedNovo NordiskAug 14, 201467
NCT01999322Diabetes Mellitus · United States, Germany3CompletedNovo NordiskMay 14, 201437
NCT01992588Diabetes Mellitus · Germany1CompletedNovo NordiskMar 201448
NCT01934712Diabetes Mellitus · Japan1CompletedNovo NordiskJan 28, 201450
NCT01924637Diabetes Mellitus · Austria1CompletedNovo NordiskNov 201336
NCT01892020Diabetes Mellitus · China4CompletedNovo NordiskMay 2014161
NCT01868568Diabetes Mellitus · Germany1CompletedNovo NordiskAug 200855
NCT01868555Diabetes Mellitus · Japan1CompletedNovo NordiskFeb 200832
NCT01865331Diabetes Mellitus · Germany1CompletedNovo NordiskMar 200732
NCT01865305Diabetes Mellitus · Germany1CompletedNovo NordiskFeb 200759
NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more3CompletedNovo NordiskNov 7, 2014362
NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more3CompletedNovo NordiskMar 201440
NCT01773798Diabetes Mellitus · Austria1CompletedNovo NordiskAug 201333
NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more3CompletedNovo NordiskJan 9, 2014274
NCT01707134Diabetes Mellitus · Austria, Denmark, Finland and more3CompletedNovo NordiskMay 2000753
NCT01704378Diabetes Mellitus · Finland, Norway, Sweden and more4CompletedNovo NordiskMar 14, 200389
NCT01698697Diabetes Mellitus · South Africa1CompletedNovo NordiskOct 18, 200224
NCT01682902Diabetes Mellitus · United States1CompletedNovo NordiskMar 201343
NCT01650129Diabetes Mellitus · Japan3CompletedNovo NordiskOct 18, 200183
NCT01620437Diabetes Mellitus · Japan1CompletedNovo NordiskDec 30, 200330
NCT01620333Diabetes Mellitus · Japan1CompletedNovo NordiskApr 200024
NCT01618188Diabetes Mellitus · Germany1CompletedNovo NordiskSep 7, 201252
NCT01538511Diabetes Mellitus · Japan1CompletedNovo NordiskMar 13, 200759
NCT01536028Diabetes Mellitus · Germany1CompletedNovo NordiskJul 200632
NCT01530048Diabetes Mellitus · Denmark1CompletedNovo NordiskMay 200634
NCT01527656Diabetes Mellitus · Germany1CompletedNovo NordiskFeb 200440
NCT01527643Diabetes Mellitus · Germany1CompletedNovo NordiskDec 17, 200330
NCT01527630Diabetes Mellitus · Japan1CompletedNovo NordiskJan 8, 200330
NCT01527565Diabetes Mellitus · South Africa1CompletedNovo NordiskFeb 26, 200330
NCT01527552Diabetes Mellitus · South Africa1CompletedNovo NordiskDec 18, 200230
NCT01526980Diabetes Mellitus · United Kingdom2CompletedNovo NordiskNov 200231
NCT01526941Diabetes Mellitus · Germany1CompletedNovo NordiskJul 200127
NCT01649570Diabetes Mellitus · Japan4CompletedNovo NordiskAug 2003123

How it is read

Names in the registry

  • “insulin aspart”, 60 entries
  • “biphasic insulin aspart”, 27 entries
  • “Faster-acting insulin aspart”, 24 entries
  • “biphasic insulin aspart 50”, 13 entries
  • “biphasic insulin aspart 70”, 12 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.